Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals has priced its initial public offering at $24.00 per share, offering 12,500,000 shares to the public, expected to generate $300 million in gross proceeds. The common stock will begin trading on Nasdaq under the ticker symbol AVIR on October 30, 2020, with the closing of the offering anticipated on November 3, 2020. The underwriters have a 30-day option to purchase an additional 1,875,000 shares. J.P. Morgan, Morgan Stanley, Evercore, and William Blair are the joint book-running managers.